Bontenbal M - Search Results

1

Growth factors. Clinical implications in breast cancer.

Klijn JG, Berns PM, Bontenbal M, Foekens JA. Klijn JG, et al. Among authors: bontenbal m. Ann N Y Acad Sci. 1993 Nov 30;698:85-101. doi: 10.1111/j.1749-6632.1993.tb17193.x. Ann N Y Acad Sci. 1993. PMID: 8279785 Review. No abstract available.

2

Clinical breast cancer, new developments in selection and endocrine treatment of patients.

Klijn JG, Berns PM, Bontenbal M, Alexieva-Figusch J, Foekens JA. Klijn JG, et al. Among authors: bontenbal m. J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):211-21. doi: 10.1016/0960-0760(92)90210-a. J Steroid Biochem Mol Biol. 1992. PMID: 1445597 Review.

3

Critical review of growth factors as clinical tools in primary and metastatic breast cancer.

Klijn JG, Berns PM, van Putten WL, Bontenbal M, Alexieva-Figusch J, Foekens JA. Klijn JG, et al. Among authors: bontenbal m. Recent Results Cancer Res. 1993;127:77-88. doi: 10.1007/978-3-642-84745-5_11. Recent Results Cancer Res. 1993. PMID: 8099227 Review. No abstract available.

4

Cell biological factors associated with the response of breast cancer to systemic treatment.

Klijn JG, Berns EM, Bontenbal M, Foekens J. Klijn JG, et al. Among authors: bontenbal m. Cancer Treat Rev. 1993 Apr;19 Suppl B:45-63. doi: 10.1016/0305-7372(93)90007-e. Cancer Treat Rev. 1993. PMID: 8481934 Review.

5

Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients.

Foekens JA, Schmitt M, van Putten WL, Peters HA, Bontenbal M, Jänicke F, Klijn JG. Foekens JA, et al. Among authors: bontenbal m. Cancer Res. 1992 Nov 1;52(21):6101-5. Cancer Res. 1992. PMID: 1394237

6

Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancer.

Bontenbal M, Planting AS, Rodenburg CJ, Dees A, Verweij J, Bartels CC, Alexieva-Figusch J, van Putten WL, Klijn JG. Bontenbal M, et al. Breast Cancer Res Treat. 1992;21(2):133-8. doi: 10.1007/BF01836959. Breast Cancer Res Treat. 1992. PMID: 1627816 Free article. Clinical Trial.

7

Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: preclinical and clinical studies.

Klijn JG, Setyono-Han B, Bakker GH, van der Burg ME, Bontenbal M, Peters HA, Sieuwerts AM, Berns PM, Foekens JA. Klijn JG, et al. Among authors: bontenbal m. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1089-95. doi: 10.1016/0960-0760(90)90471-v. J Steroid Biochem Mol Biol. 1990. PMID: 1981013 Review.

8

Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells.

Bontenbal M, Sieuwerts AM, Peters HA, Sonneveld P, Foekens JA, Klijn JG. Bontenbal M, et al. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):1097-101. doi: 10.1016/0960-0760(90)90472-w. J Steroid Biochem Mol Biol. 1990. PMID: 2285583

9

Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells.

Bontenbal M, Sieuwerts AM, Klijn JG, Peters HA, Krijnen HL, Sonneveld P, Foekens JA. Bontenbal M, et al. Br J Cancer. 1989 Nov;60(5):688-92. doi: 10.1038/bjc.1989.341. Br J Cancer. 1989. PMID: 2679851 Free PMC article.

10

Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7).

Bontenbal M, Sonneveld P, Foekens JA, Klijn JG. Bontenbal M, et al. Eur J Cancer Clin Oncol. 1988 Sep;24(9):1409-14. doi: 10.1016/0277-5379(88)90329-x. Eur J Cancer Clin Oncol. 1988. PMID: 3181264

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

60 results

Search Page

Filters